SCHEMBL4962140

SCHEMBL4962140

Cc1nc2cc(NC(=O)OC3CCCCC3)ccc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.56
NPC1 O15118 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
STAT1 P42224 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LMNA P02545 2/20 0.55
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
MAPT P10636 3/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 2/20 0.54
EPHX2 P34913 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HTT P42858 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
FAAH O00519 1/20 0.49
MGLL Q99685 1/20 0.49
TP53 P04637 2/20 0.48
MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517901 0.91 POLB (0.57) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL5520150 0.83 RAB9A (0.53) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL5523279 0.80 RAB9A (0.64) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL4968463 0.78 RAB9A (0.62) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL4970021 0.77 RAB9A (0.53) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL2490209 0.76 RAB9A (0.72) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL896581 0.75 RAB9A (0.61) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL4968596 0.74 RAB9A (0.61) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL5524308 0.74 POLB (0.54) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL14470501 0.74 RAB9A (0.66) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1969051-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2008-09-17 EP disclosed
WO-2008024139-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2008-02-28 WO disclosed
WO-2007079180-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2007-07-12 WO disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 RAB9A 2202/4885NPC1 588/4885SMN1; SMN2 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.